Alterity Therapeutics
Pharmaceuticals, Melbourne, Connecticut, 06902, United States, 11-50 Employees
Phone Number: 61**********
Who is ALTERITY THERAPEUTICS
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. Our goal is to modify the cour...
Read More
-
Headquarters: Melbourne, Connecticut, 06902, United States
-
Employees: 11-50
-
Revenue: Under $1 Million
-
CEO:
David Stamler
Email
Phone
Industry: Pharmaceuticals
Does something look wrong? Fix it. | View contact records from ALTERITY THERAPEUTICS
Alterity Therapeutics Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Alterity Therapeutics
Answer: Alterity Therapeutics's headquarters are located at Melbourne, Connecticut, 06902, United States
Answer: Alterity Therapeutics's phone number is 61**********
Answer: Alterity Therapeutics's official website is https://alteritytherapeutics.com
Answer: Alterity Therapeutics's revenue is Under $1 Million
Answer: Alterity Therapeutics has 11-50 employees
Answer: Alterity Therapeutics is in Pharmaceuticals
Answer: Alterity Therapeutics contact info: Phone number: 61********** Website: https://alteritytherapeutics.com
Answer: Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. Our goal is to modify the course of these diseases and improve quality of life. Our lead asset, ATH434, has the potential to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. ATH434 has been shown preclinically to reduce -synuclein pathology and preserve nerve cells by restoring normal iron balance in the brain. As an iron chaperone, it has excellent potential to treat Parkinsons disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA). ATH434 is currently being evaluated in a global Phase 2 clinical trial in patients with early-stage MSA. Alterity also has a broad drug discovery platform generating patentable chemical compounds to intercede in disease processes. Alterity has offices in Melbourne, Australia and San Francisco, USA.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month